Immunotherapy Clinical Trials in Beijing, Beijing Municipality
11 recruitingBeijing, Beijing Municipality, China
Showing 1–11 of 11 trials
Recruiting
Phase 2
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
Neoadjuvant TherapyImmunotherapyTislelizumab+3 more
Seventh Medical Center of PLA General Hospital50 enrolled1 locationNCT07458529
Recruiting
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
Neoadjuvant TherapyLung NeoplasmsMinimal Residual Disease+1 more
Peking University People's Hospital100 enrolled1 locationNCT07291921
Recruiting
Phase 2
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Biliary Tract Neoplasms Immunotherapy
Peking Union Medical College Hospital60 enrolled1 locationNCT06230471
Recruiting
Phase 2
The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
Gastric (Stomach) CancerImmunotherapyBiological Therapy
Chinese PLA General Hospital90 enrolled1 locationNCT07212933
Recruiting
Not Applicable
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
Colon CancerImmunotherapyMismatch Repair Deficiency
Peking Union Medical College Hospital18 enrolled2 locationsNCT06215677
Recruiting
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
RadiotherapyLung Cancer (NSCLC)Neoadjuvant Immunotherapy+1 more
Peking University Cancer Hospital & Institute500 enrolled4 locationsNCT06926179
Recruiting
Phase 2
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
Targeted TherapyImmunotherapyRadiation Therapy+1 more
Peking University First Hospital30 enrolled1 locationNCT06889649
Recruiting
Phase 2
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
Cervical CancerNeoadjuvant ChemoimmunotherapyLocally Advanced Cervical Cancer+1 more
Tongji Hospital40 enrolled12 locationsNCT06288360
Recruiting
Phase 2Phase 3
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Cervical CancerConcurrent ChemoradiotherapyNeoadjuvant Chemoimmunotherapy+1 more
Tongji Hospital440 enrolled12 locationsNCT06288373
Recruiting
Phase 2
Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Biliary Tract Neoplasms Immunotherapy
Peking Union Medical College Hospital300 enrolled1 locationNCT06362317
Recruiting
Phase 2
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
Cervical CarcinomaImmunotherapyImmune Checkpoint Inhibitor+6 more
Lei Li92 enrolled1 locationNCT05311566